Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Precipio ( (PRPO) ) has shared an announcement.
Precipio, Inc., a specialty cancer diagnostics company, announced the termination of its At-The-Market (ATM) instrument with Alliance Global Partners as of September 2, 2025. This decision reflects the company’s improved financial position, marked by the elimination of negative cash flow and increased cash balance, indicating a reduced reliance on such capital-raising tools and a commitment to enhancing shareholder value.
The most recent analyst rating on (PRPO) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Precipio stock, see the PRPO Stock Forecast page.
Spark’s Take on PRPO Stock
According to Spark, TipRanks’ AI Analyst, PRPO is a Neutral.
Precipio’s overall score is driven by strong earnings call insights and positive technical indicators. However, financial performance and valuation concerns, including ongoing losses and negative cash flow, weigh down the score. Recent corporate advancements provide a positive outlook, but profitability improvements are crucial for a higher score.
To see Spark’s full report on PRPO stock, click here.
More about Precipio
Precipio is a healthcare biotechnology company focused on cancer diagnostics. The company aims to address cancer misdiagnoses by developing diagnostic products and services that enhance accuracy, improve laboratory workflow, and lead to better patient outcomes, ultimately reducing healthcare expenses. Precipio commercializes its innovative technologies as proprietary products for the global laboratory community.
Average Trading Volume: 11,969
Technical Sentiment Signal: Hold
Current Market Cap: $25.14M
Find detailed analytics on PRPO stock on TipRanks’ Stock Analysis page.